We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that positive preliminary results from an ongoing, single-arm, open label, phase II proof-of-concept study on evinacumab in patients suffering from homozygous familial hypercholestrolemia (HoFH) were presented at the European Atherosclerosis Society Congress. Evinacumab is an experimental monoclonal antibody to angiopoietin-like protein 3.
Interim data showed that evinacumab in combination with other lipid-lowering therapies resulted in a mean reduction in low density lipoprotein cholesterol (LDL-C) in the first 4 patients by an additional 55% at week 4 compared to baseline, which was also the primary endpoint of the study. Between these 4 patients, the percent reductions in LDL-C ranged from 25–90%. Overall, the patients enrolled in the study saw their mean LDL-C levels decrease from 331mg/dL at baseline to 175mg/dL at week 4.
On the safety front, evinacumab was found to be well tolerated with no adverse event being reported leading to discontinuation. Meanwhile, the study is targeting to enrol up to 8 patients with HoFH.
We are encouraged by the company’s progress with the candidate. The cholesterol management market represents a huge commercial potential.
We note that Regeneron received a huge boost when Praluent became the first PCSK9 inhibitor to gain approval in the U.S. The drug is also approved in the EU. Regeneron has co-developed Praluent with Sanofi (SNY - Free Report) . The current payer restrictions are limiting the product’s uptake though the companies expect a gradual uptick in sales.
PCSK9 inhibitors work by inhibiting PCSK9, a protein that reduces the liver's ability to remove "bad" cholesterol from the blood. Amgen Inc.’s (AMGN - Free Report) PCSK9 inhibitor, Repatha, is also approved both in the U.S and EU.
Regeneron is a Zack Rank #3 (Hold) stock. ANI Pharmaceuticals, Inc. (ANIP - Free Report) is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that positive preliminary results from an ongoing, single-arm, open label, phase II proof-of-concept study on evinacumab in patients suffering from homozygous familial hypercholestrolemia (HoFH) were presented at the European Atherosclerosis Society Congress. Evinacumab is an experimental monoclonal antibody to angiopoietin-like protein 3.
Interim data showed that evinacumab in combination with other lipid-lowering therapies resulted in a mean reduction in low density lipoprotein cholesterol (LDL-C) in the first 4 patients by an additional 55% at week 4 compared to baseline, which was also the primary endpoint of the study. Between these 4 patients, the percent reductions in LDL-C ranged from 25–90%. Overall, the patients enrolled in the study saw their mean LDL-C levels decrease from 331mg/dL at baseline to 175mg/dL at week 4.
On the safety front, evinacumab was found to be well tolerated with no adverse event being reported leading to discontinuation. Meanwhile, the study is targeting to enrol up to 8 patients with HoFH.
We are encouraged by the company’s progress with the candidate. The cholesterol management market represents a huge commercial potential.
We note that Regeneron received a huge boost when Praluent became the first PCSK9 inhibitor to gain approval in the U.S. The drug is also approved in the EU. Regeneron has co-developed Praluent with Sanofi (SNY - Free Report) . The current payer restrictions are limiting the product’s uptake though the companies expect a gradual uptick in sales.
PCSK9 inhibitors work by inhibiting PCSK9, a protein that reduces the liver's ability to remove "bad" cholesterol from the blood. Amgen Inc.’s (AMGN - Free Report) PCSK9 inhibitor, Repatha, is also approved both in the U.S and EU.
Regeneron is a Zack Rank #3 (Hold) stock. ANI Pharmaceuticals, Inc. (ANIP - Free Report) is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>